

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Mepolizumab for treating hypereosinophilic syndrome ID3749

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u> GlaxoSmithKline (mepolizumab)</p> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Allergy UK • Brain Charity • Brain and Spine Foundation • British Lung Foundation • EOS Network • Guts UK • NARA – The Breathing Charity • National Eczema Society • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association for Respiratory Technology and Physiology • Association of Respiratory Nurse Specialists • British Association of Dermatologists • British Cardiovascular Society • British Committee for Standards in Haematology • British Dermatological Nursing Group • British Geriatrics Society • British Neuropathological Society • British Skin Foundation • British Society for Allergy and Clinical Immunology • British Society for Cutaneous Allergy • British Society for Haematology • British Society for Immunology • British Thoracic Society • ILD-IN: Interstitial Lung Diseases Interdisciplinary Network • Institute of Neurology • National Heart and Lung Institute • NHS Blood and Transplant • Primary Care Neurology Society • Primary Care Dermatology Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehovah’s Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Aspen Pharma (azathioprine) • Aurobindo Pharma – Milpharm (imatinib) • Bristol-Myers Squibb (hydroxycarbamide) • Cipla EU (imatinib) • Dixel Pharma (ciclosporin) • Dr. Reddy’s Laboratories UK (imatinib) • Ennogen Pharma (azathioprine) • Intrapharm Laboratories (imatinib) • Medac Pharma UK (hydroxycarbamide) • Mylan (azathioprine, ciclosporin) • Novartis (ciclosporin, imatinib) • Rivopharm UK (imatinib) • Roche (interferon-alpha) • Sandoz (imatinib) • Sanofi Genzyme (alemtuzumab) • Tillomed (azathioprine) • Wockhardt UK (imatinib)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Primary Immunodeficiency Network • UK National Screening Committee • Vascular Society of Great Britain and Northern Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Ealing CCG • NHS England • NHS South Cheshire CCG • Welsh Government 	<ul style="list-style-type: none"> • Zentiva (imatinib) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Association for Lung Research • British Epidermo-Epidemiology Society • Circulation Foundation • Cochrane Airways Group • Cochrane Skin Group • Genomics England • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research • Skin Treatment and Research Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not share it. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the evaluation; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the

Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.